Envoy Medical (COCH) EPS (Weighted Average and Diluted) (2021 - 2026)

Envoy Medical has disclosed EPS (Weighted Average and Diluted) across 6 years of filings, most recently posting -$0.08 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.08, up 72.41% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.01 (up 26.28% YoY), and the FY2025 annual result was -$1.23, up 17.45% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.08 for Q1 2026 at Envoy Medical, up from -$0.26 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.23 in Q1 2022 to a low of -$1.31 in Q1 2023.
• The 5-year median for EPS (Weighted Average and Diluted) is -$0.29 (2024), against an average of -$0.3.
• Peak annual rise in EPS (Weighted Average and Diluted) reached 500.0% in 2022, while the deepest fall reached 927.27% in 2022.
• Envoy Medical's EPS (Weighted Average and Diluted) stood at -$1.13 in 2022, then jumped by 92.92% to -$0.08 in 2023, then plunged by 400.0% to -$0.4 in 2024, then surged by 35.0% to -$0.26 in 2025, then surged by 69.23% to -$0.08 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.08 (Q1 2026), -$0.26 (Q4 2025), and -$0.35 (Q3 2025), per Business Quant data.